Chronic pain is frequently comorbid with opioid abuse and severe depression, a combination that greatly compounds suicide risk. In addition to the therapeutic value of buprenorphine in addiction and analgesia, growing evidence suggests potential use as an antidepressant. Data supporting buprenorphine antisuicidal properties are scarce. We aim to contribute to the discussion of buprenorphine antisuicidal potential in patients with significant psychiatric and medical comorbidity.
Methods
We performed a chart review of suicidal adult depressed patients with comorbid chronic pain and opioid use disorder who received off-label buprenorphine in outpatient and inpatient settings in a university hospital between 2013 and 2016.
Results
Four of the patients had an early positive response. However, only three continue to adhere to treatment for six months or longer.
Conclusions
More severe opioid use disorder seems to more negatively influence clinical outcome, independently of cluster b personality traits. Identification of patients who could benefit from buprenorphine will require further studies.
Jimenez-RodriguezIGarcia-LeivaJMJimenez-RodriguezBM, et al.
Suicidal ideation and the risk of suicide in patients with fibromyalgia: a comparison with non-pain controls and patients suffering from low-back pain. Neuropsychiatr Dis Treat2014;
10: 625–630.
5.
CacedaRKordsmeierNCGoldenE, et al.
Differential processing of physical and psychological pain during acute suicidality. Psychother Psychosom2017;
86: 116–118.
6.
OrbachIPalgiYSteinD, et al.
Tolerance for physical pain in suicidal subjects. Death Stud1996;
20: 327–341.
7.
OrbachISteinDPalgiY, et al.
Perception of physical pain in accident and suicide attempt patients: self-preservation vs self-destruction. J Psychiatr Res1996;
30: 307–320.
8.
OrbachIMikulincerMKingR, et al.
Thresholds and tolerance of physical pain in suicidal and nonsuicidal adolescents. J Consult Clin Psychol1997;
65: 646–652.
9.
ShneidmanES.Suicide as psychache. J Nerv Ment Dis1993;
181: 145–147.
YagerJ.Addressing patients’ psychic pain. Am J Psychiatry2015;
172: 939–943.
12.
OrbachIMikulincerMSirotaP, et al.
Mental pain: a multidimensional operationalization and definition. Suicide Life Threat Behav2003;
33: 219–230.
13.
BaumeisterRF.Suicide as escape from self. Psychol Rev1990;
97: 90–113.
14.
MeerwijkELWeissSJ.Toward a unifying definition of psychological pain. J Loss Trauma2011;
16: 402–412.
15.
Chavez-HernandezAMLeenaarsAAChavez-de SanchezMI, et al.
Suicide notes from Mexico and the United States: a thematic analysis. Salud Publica Mex2009;
51: 314–320.
16.
CácedaRDurandDCortesE, et al.
Impulsive choice and psychological pain in acutely suicidal depressed patients. Psychosom Med2014;
76: 445–451.
17.
OlieEGuillaumeSJaussentI, et al.
Higher psychological pain during a major depressive episode may be a factor of vulnerability to suicidal ideation and act. J Affect Disord2010;
120: 226–230.
18.
DucasseDHoldenRRBoyerL, et al.
Psychological pain in suicidality: a meta-analysis. J Clin Psychiatry2018;
79: 16r10732.
19.
ElmanIBorsookDVolkowND.Pain and suicidality: insights from reward and addiction neuroscience. Prog Neurobiol2013;
109: 1–27.
20.
GordonACallaghanDSpinkD, et al.
Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther2010;
32: 844–860.
21.
KarpJFButtersMABegleyAE, et al.
Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry2014;
75: E785–E93.
22.
EmrichHMVogtPHerzA, et al.
Antidepressant effects of buprenorphine. Lancet1982;
2: 709.
23.
FavaMMemisogluAThaseME, et al.
Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry2016;
173: 499–508.
24.
StriebelJMKalapatapuRK.The anti-suicidal potential of buprenorphine: a case report. Int J Psychiatry Med2014;
47: 169–174.
25.
YovellYBarGMashiahM, et al.
Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry2016;
173: 491–498.
26.
NorelliLJSmithHSSherL, et al.
Buprenorphine in the treatment of non-suicidal self-injury: a case series and discussion of the literature. Int J Adolesc Med Health2013;
25: 323–330.
27.
American Psychiatric Association.Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Publication,2000.
28.
KroenkeKSpitzerRLWilliamsJB.The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med2001;
16: 606–613.
29.
HeelRCBrogdenRNSpeightTM, et al.
Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs1979;
17: 81–110.
30.
DeWallCNMacDonaldGWebsterGD, et al.
Acetaminophen reduces social pain: behavioral and neural evidence. Psychol Sci2010;
21: 931–937.
31.
WilliamsNRHeifetsBDBlaseyC, et al.
Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry2018;
175: 1205–1215.
